Eupraxia Pharmaceuticals (EPRX) Depreciation & Amortization (CF) (2023 - 2025)
Eupraxia Pharmaceuticals' (EPRX) quarterly Depreciation & Amortization (CF) came in at $72806.0 in Q4 2025, up 33.56% year-on-year from $54512.0 in Q4 2024, and up 15.58% on a QoQ basis from $62993.0 in Q3 2025.
Eupraxia Pharmaceuticals (EPRX) Depreciation & Amortization (CF) (2023 - 2025) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has 3 years of Depreciation & Amortization (CF) data on file, last reported at $72806.0 in Q4 2025.
- On a quarterly basis, Depreciation & Amortization (CF) rose 33.56% year-over-year to $72806.0 in Q4 2025; TTM through Mar 2026 was $191230.0, a 5.78% increase from a year earlier, with the FY2025 full-year figure at $237717.0, up 38.43% from the prior year.
- Depreciation & Amortization (CF) for Q4 2025 stood at $72806.0, up from $62993.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for EPRX reached as high as $72806.0 in Q4 2025 and fell as low as $37418.0 in Q1 2024.
- Historically, Depreciation & Amortization (CF) has averaged $47080.2 across 3 years, with a median of $41631.5 in 2023.
- Across the five-year window, Depreciation & Amortization (CF) slipped 2.47% in 2024 and soared 66.83% in 2025, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $41233.0 in 2023, then jumped by 32.2% to $54512.0 in 2024, then surged by 33.56% to $72806.0 in 2025.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $72806.0 in Q4 2025, $62993.0 in Q3 2025, and $55431.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Eupraxia Pharmaceuticals | 357.29 Mn | 355.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 72,806.00 |
| Dec 31, 2025 | 72,806.00 |
| Sep 30, 2025 | 62,993.00 |
| Sep 30, 2025 | 62,993.00 |
| Jun 30, 2025 | 55,431.00 |
| Jun 30, 2025 | 55,431.00 |
| Mar 31, 2025 | 46,487.00 |
| Mar 31, 2025 | 46,487.00 |
| Dec 31, 2024 | 54,512.00 |
| Dec 31, 2024 | 54,512.00 |
| Sep 30, 2024 | 37,759.00 |
| Sep 30, 2024 | 37,759.00 |
| Jun 30, 2024 | 42,030.00 |
| Jun 30, 2024 | 42,030.00 |
| Mar 31, 2024 | 37,418.00 |
| Mar 31, 2024 | 37,418.00 |
| Dec 31, 2023 | 41,233.00 |
| Dec 31, 2023 | 41,233.00 |
| Sep 30, 2023 | 38,716.00 |
| Sep 30, 2023 | 38,716.00 |